查看文章

Combining certain drugs that target specific proteins in cancer cells has been found to help people with advanced non-small cell lung cancer live longer. We systematically reviewed several clinical trials and synthesized evidence to see how well the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anti-vascular endothelial growth factor receptor (anti-VEGFR) combination treatment works. These drugs target specific proteins involved in cancer growth. We found that when EGFR-TKI is used together with another drug that blocks blood vessel growth (anti-VEGFR), they can delay the cancer from getting worse, but they do not necessarily make people live longer overall. This seems to be true irrespective of whether the treatment is used as the first option or later, and whether it’s an older or newer type of the EGFR-TKI drug.

Introduction: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in combination with anti-vascular endothelial growth factor receptor (VEGFR) agents have shown improved survival outcomes in recent studies. However, its efficacy related to survival outcomes as a first- or second-line agent and based on generations remains to be explored. This study estimated the survival outcomes of EGFR-TKIs plus anti-VEGFR in combination in defined populations of advanced non-small cell lung cancer (NSCLC) patients overall, as a first- or second line of treatment, with different generations of EGFR-TKIs and EGFR-TKIs plus bevacizumab combination as a subgroup. Methods: A literature search was conducted using PubMed …